Tal Rosenberg to Lead Apollo Intelligence as New Chief Executive Officer
17.9.2024 17:30:00 CEST | Business Wire | Press Release
Apollo Intelligence (Apollo), a leading global provider of high-quality, real-time insights to the life sciences and healthcare industries, announces the appointment of Tal Rosenberg as Chief Executive Officer.
Rosenberg is a technology executive with an exceptional track record of using data and technology to transform Life Sciences businesses for both Fortune 100 and PE-backed companies. Known for inspiring teams to drive digitally-forward, customer-centric innovations, he will focus on advancing growth by expanding the capabilities and offerings of the Apollo technology platform.
Powered by artificial intelligence, Apollo directly connects clients to a highly engaged, global panel of healthcare professionals who respond to research at industry-leading rates.
“Apollo delivers on a critical need to accelerate drug development and launch effectiveness through its real-time primary market insights, and we are well-positioned to broaden our insight offerings through new data ingestion and analytics,” said Tai Rosenberg. “I am thrilled to join the team as we transform the market, bringing greater value to clients and partners.”
In his prior role as President and GM of the Life Sciences, Ecosystem and Public Sector business unit at Datavant, Rosenberg led the development of the world’s largest Real World Data (RWD) ecosystem, including a patient privacy record linkage platform. Before that, he led IQVIA Technologies, launching SaaS applications and services from molecule to market.
Rosenberg succeeds Dan Fitzgerald, Apollo’s founder and previous CEO. "Over the last five years, Apollo’s talented team has doubled revenue by delivering highly differentiated product innovation and superior client satisfaction. Tal’s leadership and deep expertise in life sciences, technology, and building transformational industry partnerships, will help drive our next phase of growth. I am thrilled that Apollo’s more than 300 clients, employees, and our future vision and success will be in such capable hands," said Fitzgerald. Dan will serve as a Board Advisor going forward to ensure a seamless transition.
To address accelerated drug launch timelines and the need for dynamic market learning, Apollo has modernized how life sciences leaders stay ahead of changing market dynamics through its mobile connected audiences and real-time insights platform.
Christina Reszka, investment partner at Frazier Healthcare Partners and board member of Apollo, shared, “The Apollo team is well-positioned to change the way the healthcare industry sources and applies primary market insights and data. We are incredibly thankful for Dan Fitzgerald's leadership, which has been a critical factor in building Apollo’s strong foundation and industry leading brand. I look forward to supporting Tal’s strategic vision for the future.”
About Apollo Intelligence
Apollo Intelligence is a leading insights platform purpose-built to drive greater impact for Life Sciences. Our panel of highly engaged, global healthcare professionals gives partners 24/7 access to some of medicine’s most relevant minds, while our mobile-first quantitative and qualitative research capabilities ensure more responsive and high-quality engagement. We combine human expertise, modern methodologies, and innovative digital tools to better connect the dots across all sources of market intelligence and give our healthcare partners the fast and focused understanding necessary to outpace change. Apollo’s family of brands include InCrowd, Survey Healthcare Global, and GlocalMind.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917612396/en/
Contacts
Nemesh Patel
VP, Marketing
Nemesh.patel@apollointelligence.net
+1-617-875-8177
Mary Kae Marinac
PR Representative for Apollo Intelligence
mk@mkmarinac.com
+1-978-685-3136
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom